NEW YORK — AMLo Biosciences said Tuesday that it has received UK Conformity Assessed (UKCA) marking for its AMBLor test for identifying early-stage melanomas at low risk of progression.
Latest News
UQ professor discusses ‘new technologies’ in melanoma research
The University of Queensland’s Professor Peter Soyer discusses his team’s “new” technology in the melanoma research field.
Why are Tasmanians more likely to experience sunburn?
Recent data shows that Tasmanians are more likely to experience sunburn than other Australians.
Oncology Community Mourns the Loss of Dr Jeffrey S. Weber, 2016 Giant of Cancer Care® Winner
Jeffrey S. Weber, MD, PhD, inductee of the 2016 Giants of Cancer Care® award in Melanoma, has died.